The FDA and IRB Approves the Initiation of Phase IIb TACTI-003 Trial by Immutep Limited (NASDAQ: IMMP) in the United States

It is imperative to harness and strengthen the power of the body’s immune system. This means embracing therapeutic intervention, perhaps through the use of immunotherapy treatments. Within its operations of developing novel LAG-3 related to such treatments, Immutep Limited (NASDAQ: IMMP) has announced the approval by the FDA for the […]


Immutep Limited (NASDAQ: IMMP) to Assess Efti in Tripartite Grouping Treatment Phase I Learning

Immutep Limited (NASDAQ: IMMP) proclaims it has initialed a contract to begin a new Phase I pilot, called INSIGHT-003. The pilot will assess the mixture of principal creation applicant “efti” or “IMP321” combined with an obtainable accepted customary of care treatment containing a chemotherapy go-between and an anti-PD-1 treatment. INSIGHT-003 […]